Akari Therapeutics Issues 2025 End of Year Letter to Shareholders
View original at globenewswire.comAkari Therapeutics Issues 2025 End of Year Letter to Shareholders TAMPA, Fla. and LONDON, Dec…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both single agent and in combination
80% confidencePH1's 1-2 punch mechanism has been demonstrated to improve therapeutic durability, depth of response and remissions and significantly extend survival of preclinical models relative to current ADC therapies
80% confidenceSITC submission was noted as one of the top 150 submissions at the conference and garnered great enthusiasm from academic researchers and pharmaceutical scientists
80% confidenceAKTX-101 demonstrated compelling activity in both urothelial (bladder) and gastric cancer preclinical models
80% confidenceEntering Phase 1 clinical studies will be a unique inflection point that historically correlates with increased visibility, investor interest and potential strategic partnerships
80% confidenceAKTX-101 has shown significant activity and prolonged survival relative to ADCs with traditional payloads in preclinical studies
80% confidencePH1 payload was specifically designed to overcome key limitations of existing ADC payload classes by delivering potent cytotoxic activity, unique immune activation, and differentiated safety profile
80% confidence2026 will be a pivotal and transformational year for Akari Therapeutics
80% confidencePreclinical improvements are believed to translate into superior outcomes for cancer patients in future clinical trials
80% confidence2025 was a year of meaningful progress and significant achievements towards creating best-in-class ADCs to transform current cancer therapies
80% confidencePartnership with WuXi XDC signals confidence that one of the best global partners wants to work with Akari to advance its innovative ADC into clinical trials
80% confidencePartnering with WuXi XDC enables Akari to quickly advance AKTX-101 toward first-in-human trials planned for late 2026 or early 2027, subject to regulatory clearance
80% confidenceSafety profile of AKTX-101 suggests potential for improved tolerability in clinical settings compared to current Trop2 ADCs
80% confidence